Strategy Simplified S22E18: Life Sciences Consulting in 2026: Impact at Scale
Feb 27, 2026
Doug Martin, Guidehouse practice lead with deep life sciences strategy and analytics experience, and Kaiming Poo, ClearView partner focused on growth and product planning, discuss where AI actually drives value. They cover translating complex science into commercial strategy. They also talk hiring signals, go-to-market planning, and precision medicine scaling.
AI Snips
Chapters
Transcript
Episode notes
From Korea To The US A Biotech's Build Out Story
- Kaiming Poo recounted helping a Korean biotech build a U.S. subsidiary and investor story from ideation to public unveiling.
- The engagement included capability reviews, M&A targets, leadership hiring, valuations, and investor communications.
AI Is Already Transforming Forecasts And Research
- AI is ubiquitous across life sciences and is rapidly moving from augmented search to trustworthy analytic drafts that rival bespoke research.
- Doug Martin noted AI-produced forecasts can beat Wall Street analysts using clients' data lakes and assisted tools.
Population Genomics Enables Precision Health At Scale
- National genomics programs plus AI enable population-scale precision health decisions rather than just precision medicine.
- Elsie described UAE sequencing 802,000 genomes and GCC programs using genomics plus clinical data to prioritize screening and reference labs.